iNCOVACC
Bharat Biotech’s intranasal vaccine, BBV154 or Incovacc is the world’s first intranasal vaccine to be approved as a booster dose for COVID-19.
- The nasal vaccine is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein.
- As the vaccine is given nasally, it triggers an immune response in the mucosal membrane.
- BBV154 may produce local antibodies in the upper respiratory tract which may provide the potential to reduce infection and transmission.
- This is the second heterologous booster to be included in the vaccination programme after ....
Do You Want to Read More?
Subscribe Now
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Related Content
- 1 Right to Change Name
- 2 Prevention of Damage to Public Property
- 3 Jan Vishwas (Amendment of Provisions) Act 2023
- 4 Rule 176 vs. Rule 267 of Rajya Sabha
- 5 Digital India Land Records Modernization Programme (DILRMP)
- 6 Right to Silence
- 7 Vibrant Villages Programme
- 8 Bribery Not Protected by Parliamentary Privileges: SC
- 9 SC Directions for Effective Implementation of POSH Act, 2013
- 10 e-Court Phase III
Current Affairs
- 1 High-Powered Committee on Ladakh
- 2 Corrupt Practices under Representation of People Act, 1951
- 3 Section 69(A) of Information Technology Act, 2000
- 4 Article 105 of Constitution: The Limits to Free Speech in Parliament
- 5 Special Category Status
- 6 Government sets up Panel on Digital Competition Law
- 7 Guillotine in Parliament
- 8 Rule 357 of Rules of Procedure and Conduct of Business in Lok Sabha
- 9 Delegated Legislation
- 10 Rule 267 of Rajya Sabha Rule Book
